摘要
肾细胞癌是肾脏最常见的恶性肿瘤,其早期症状不明显,有相当一部分患者在发现时已经有转移。肾癌对放化疗皆不敏感,以舒尼替尼为代表的受体酪氨酸激酶抑制剂类分子靶向药物,因具抗血管生成作用,是治疗转移性肾癌的一线方法。尽管舒尼替尼在治疗肾癌方面取得了巨大的成功,随着治疗的进行,耐药的出现几乎不可避免。在人类的基因组中,转录的序列绝大多数为非编码转录物,其中微小RNA、长链非编码RNA和环状RNA被认为在肿瘤的发生、进展过程中发挥着重要的调节作用,文章就针对非编码RNA与肾细胞癌对舒尼替尼敏感性关系的研究做一综述。
Renal cell carcinoma is the most common malignancy in the kidney and its early symptoms are insignificant,with a significant proportion of patients already having metastases when they diagnosed. Renal cell carcinoma is not sensitive to radiotherapy and chemotherapy,which made sunitinib,a receptor tyrosine kinase inhibitor,to be the first-line treatment of metastatic renal cell carcinoma because of its anti-angiogenic effect. Despite the huge success of sunitinib in the treatment of kidney cancer,the emergence of resistance is almost inevitable as treatment progresses. In the human genome,the vast majority of transcribed sequences are noncoding transcripts. Among them,microRNA,long-non-coding RNA(lncRNA),and circular RNA are considered to play an important role in tumorigenesis and progression. In this review,we summarize the microRNAs and lncRNAs that linked to the renal cell carcinoma’s resistance to sunitinib.
作者
王宇昊
王增军
WANG Yuhao;WANG Zengjun(Department of Urology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2021年第1期149-153,共5页
Journal of Nanjing Medical University(Natural Sciences)
基金
国家自然科学基金(81771640)
南京市科学技术委员会课题[201605001(JA16)]。
